Developer docs
API playgroundTry for free, no card

Search company profiles

Ampleia

Full company profile

uuid000ij82

Namestring
Ampleia
Legal namestring
AMPLEIA SAS
Websiteurl
ampleia.eu
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Ampleia SAS is a French venture builder founded in 2023 and headquartered in Évry-Courcouronnes (with operating presence in Paris, 75013) that builds and co-constructs biotech companies developing therapeutics for rare diseases. The firm operates a four-step disciplined approach: sourcing the best rare-disease research teams worldwide, assembling execution-focused teams of operators, scientists, and investors, advancing programs with clinical rigor, and delivering financial returns to investors and clinical benefits to patients. Its core platform is a network of 6,000+ medical and scientific experts across all technology modalities, anchored by deep operational ties to the AFM-Telethon/Genethon ecosystem, which has invested €1.7B in rare-disease R&D since 1958 and supports 38 clinical trials across 28 indications.

The company's portfolio includes legacy spin-offs Genosafe (CRO for gene and cell therapy, founded 2003), BIMR (2013, 7 companies supported with BPIfrance), Yposkesi (CDMO for gene and cell therapy, 2016), and Atamyo Therapeutics (gene therapy for muscular dystrophies, 2020), plus two current stealth-stage programs — one in immunology targeting novel metabolite transport and another in neurosciences building a large-payload gene-therapy delivery platform. The leadership team is drawn from Genethon, Sanofi, OSE Immunotherapeutics, Nanobiotix, Gensight, Imagine Institute, and AFM-Telethon, with an Investment Committee comprising Accure Therapeutics' CEO, AFM-Telethon's Operations & Innovation Director, AFM-Telethon's Scientific Director (also President of Genosafe), and the CSO of Neuvasq.

Ampleia monetizes through equity returns and licensing/royalty arrangements tied to its portfolio companies rather than direct product sales; no revenue figures, funding rounds, or external investors are publicly disclosed. GTM is enterprise field sales targeting pharma, biotech, and academic institutions in rare disease for partnership and sourcing opportunities. Customer-facing segments are research teams (primary), rare disease patients (primary beneficiary), and investors in the rare-disease space (financial beneficiaries). Distribution occurs via the firm's website (www.ampleia.eu), a monthly newsletter, thought-leadership articles, and convening events such as the Ampleia Health Innovation Summit 2026 at Station F, Paris.

Short descriptiontext

Ampleia is a French venture builder, founded in 2023, that creates and supports biotech companies developing rare-disease therapeutics, drawing on a network of 6,000+ medical and scientific experts and the AFM-Telethon ecosystem's 65+ year legacy in rare-disease R&D.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersÉvry, France
HQ citystring
Évry
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease therapeutics, biotech venture building, gene therapy development, translational research, orphan drug development
Industry3 codes
PRIMARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGAOAB
Data Management, Biostatistics & Statistical Programming FSP
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Scientific Staffing & Functional Service Providers (FSP)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Biotech Venture Building
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Equity returns from portfolio companies
TypeLicensing Royalties
Description

As a venture-builder, Ampleia generates returns through equity stakes in portfolio companies built from identifying best research teams, assembling execution-focused teams, and advancing programs through clinical development to deliver high clinical benefits to patients and meaningful financial returns to investors.

ampleia.eu
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Ampleia is a venture builder that identifies breakthrough research teams in rare diseases worldwide, assembles execution-focused teams of operators, scientists, and investors, and advances programs through clinical development to create biotech companies. The firm manages a portfolio of portfolio companies and spinoffs (Genosafe, Yposkesi, Atamyo Therapeutics) plus active stealth-stage biotechs in immunology and neurosciences, capturing equity and licensing/royalty returns while delivering clinical benefits to patients with rare diseases.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 218k€ annual price per patient vs 13k€ for common diseases
+2 more records
Product overview1 text field

Ampleia is a venture-builder for rare diseases that builds and co-constructs biotech companies from their earliest stages. The company operates a portfolio of ventures including Genosafe (CRO for gene and cell therapy, 2003), Yposkesi (CDMO for gene and cell therapy, 2016), and Atamyo Therapeutics (gene therapy for muscular dystrophies, 2020). Current active programs include two stealth-stage biotech companies — one developing a first-in-class therapeutic targeting novel metabolite transport in immunology, and another building a gene-therapy platform for large payload delivery in neurosciences. Ampleia identifies breakthrough science worldwide, assembles execution-focused teams, and advances programs with clinical rigor through a network of 6,000+ medical and scientific experts to deliver high clinical benefits to patients and financial returns to investors.

Product and service5 records
1Stealth Biotech (Immunology)
CategoryPortfolio company — Immunology therapeutics
Description

Stealth-stage biotechnology company developing a first-in-class therapeutic targeting novel metabolite transport for immunology applications; built by Ampleia as part of its rare-disease venture-builder portfolio.

2Stealth Biotech (Neurosciences)
CategoryPortfolio company — Neurosciences gene-therapy platform
Description

Stealth-stage company developing a gene-therapy platform enabling large payload delivery for neurosciences applications; built by Ampleia within its rare-disease venture-builder portfolio.

3Genosafe
CategorySpinoff company — CRO for gene and cell therapy
Description

Contract research organization (CRO) specializing in gene and cell therapy, founded in 2003; part of Ampleia's venture-builder legacy portfolio. Serge Braun serves as its President.

4Yposkesi
CategorySpinoff company — CDMO for gene and cell therapy
Description

Contract development and manufacturing organization (CDMO) for gene and cell therapy, created in 2016; part of Ampleia's venture-builder legacy portfolio.

5Atamyo Therapeutics
CategorySpinoff company — Gene therapy for muscular dystrophies
Description

Gene therapy company focused on muscular dystrophies, founded in 2020, advancing programs for LGMD-R5 and other rare neuromuscular diseases; built from Genethon research by Ampleia's venture builder.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierPortfolioTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Atamyo, created in 2020, focuses on gene therapy for muscular dystrophies. Pierre-Albert Colcomb was instrumental in Atamyo's creation. Portfolio company building on Genethon research.

2Yposkesi
Strategic tierPortfolioTypeStrategic or Co-development PartnerAnnounced on2016-01-01
Description

Yposkesi, created in 2016, is a CDMO for gene and cell therapy. Part of Ampleia's venture-builder legacy portfolio of companies.

ampleia.eu
Strategic tierPortfolioTypeStrategic or Co-development PartnerAnnounced on2003-01-01
Description

Genosafe, founded in 2003, is a CRO for gene and cell therapy. Serge Braun is President of Genosafe. Part of Ampleia's venture-builder legacy.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

AFM-Telethon is a renowned partner fighting rare diseases for 65+ years since 1958. They have invested €1.7b in R&D for rare diseases, have 550+ FTEs and 215k+ volunteers, and maintain a wide international network. Ampleia's legacy and track-record is deeply connected to AFM-Telethon's expertise.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Genethon, founded in 2003, is a CRO for gene and cell therapy. Ampleia President Alexandre Lemoalle is Head of Strategic Projects at Genethon. Genethon's foundational research has helped advance sarcoglycan-targeting gene therapy approaches through Atamyo Therapeutics.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ampleia

Biotech Venture Buildingampleia.eu

Ampleia is a French venture builder, founded in 2023, that creates and supports biotech companies developing rare-disease therapeutics, drawing on a network of 6,000+ medical and scientific experts and the AFM-Telethon ecosystem's 65+ year legacy in rare-disease R&D.

What Ampleia does

Ampleia SAS is a French venture builder founded in 2023 and headquartered in Évry-Courcouronnes (with operating presence in Paris, 75013) that builds and co-constructs biotech companies developing therapeutics for rare diseases. The firm operates a four-step disciplined approach: sourcing the best rare-disease research teams worldwide, assembling execution-focused teams of operators, scientists, and investors, advancing programs with clinical rigor, and delivering financial returns to investors and clinical benefits to patients. Its core platform is a network of 6,000+ medical and scientific experts across all technology modalities, anchored by deep operational ties to the AFM-Telethon/Genethon ecosystem, which has invested €1.7B in rare-disease R&D since 1958 and supports 38 clinical trials across 28 indications.

The company's portfolio includes legacy spin-offs Genosafe (CRO for gene and cell therapy, founded 2003), BIMR (2013, 7 companies supported with BPIfrance), Yposkesi (CDMO for gene and cell therapy, 2016), and Atamyo Therapeutics (gene therapy for muscular dystrophies, 2020), plus two current stealth-stage programs — one in immunology targeting novel metabolite transport and another in neurosciences building a large-payload gene-therapy delivery platform. The leadership team is drawn from Genethon, Sanofi, OSE Immunotherapeutics, Nanobiotix, Gensight, Imagine Institute, and AFM-Telethon, with an Investment Committee comprising Accure Therapeutics' CEO, AFM-Telethon's Operations & Innovation Director, AFM-Telethon's Scientific Director (also President of Genosafe), and the CSO of Neuvasq.

Ampleia monetizes through equity returns and licensing/royalty arrangements tied to its portfolio companies rather than direct product sales; no revenue figures, funding rounds, or external investors are publicly disclosed. GTM is enterprise field sales targeting pharma, biotech, and academic institutions in rare disease for partnership and sourcing opportunities. Customer-facing segments are research teams (primary), rare disease patients (primary beneficiary), and investors in the rare-disease space (financial beneficiaries). Distribution occurs via the firm's website (www.ampleia.eu), a monthly newsletter, thought-leadership articles, and convening events such as the Ampleia Health Innovation Summit 2026 at Station F, Paris.

Ampleia firmographics

Firmographics
Name
Ampleia
Legal name
AMPLEIA SAS
Website
https://ampleia.eu
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
1–10 employees
Short description
Ampleia is a French venture builder, founded in 2023, that creates and supports biotech companies developing rare-disease therapeutics, drawing on a network of 6,000+ medical and scientific experts and the AFM-Telethon ecosystem's 65+ year legacy in rare-disease R&D.
Ownership category
akta.pro rank

Ampleia industry classification

Industry
Product category
Biotech Venture Building
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGAOAB
Data Management, Biostatistics & Statistical Programming FSP
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Scientific Staffing & Functional Service Providers (FSP)

Keywords

  • Rare disease therapeutics
  • Biotech venture building
  • Gene therapy development
  • Translational research
  • Orphan drug development

Where Ampleia is headquartered

Location

Headquarters

HQ city
Évry
HQ country
France
HQ region
Europe

Offices2 records

Markets served

Ampleia business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

  1. Equity returns from portfolio companies: As a venture-builder, Ampleia generates returns through equity stakes in portfolio companies built from identifying best research teams, assembling execution-focused teams, and advancing programs through clinical development to deliver high clinical benefits to patients and meaningful financial returns to investors.

Go-to-market motion1 record

Marketing channels4 records

Ampleia product offering

Product offering

Core offering

Ampleia is a venture builder that identifies breakthrough research teams in rare diseases worldwide, assembles execution-focused teams of operators, scientists, and investors, and advances programs through clinical development to create biotech companies. The firm manages a portfolio of portfolio companies and spinoffs (Genosafe, Yposkesi, Atamyo Therapeutics) plus active stealth-stage biotechs in immunology and neurosciences, capturing equity and licensing/royalty returns while delivering clinical benefits to patients with rare diseases.

Product overview

Ampleia is a venture-builder for rare diseases that builds and co-constructs biotech companies from their earliest stages. The company operates a portfolio of ventures including Genosafe (CRO for gene and cell therapy, 2003), Yposkesi (CDMO for gene and cell therapy, 2016), and Atamyo Therapeutics (gene therapy for muscular dystrophies, 2020). Current active programs include two stealth-stage biotech companies — one developing a first-in-class therapeutic targeting novel metabolite transport in immunology, and another building a gene-therapy platform for large payload delivery in neurosciences. Ampleia identifies breakthrough science worldwide, assembles execution-focused teams, and advances programs with clinical rigor through a network of 6,000+ medical and scientific experts to deliver high clinical benefits to patients and financial returns to investors.

Differentiator

Problem solved

Functional benefit

Products and services

  • Stealth Biotech (Immunology) Stealth-stage biotechnology company developing a first-in-class therapeutic targeting novel metabolite transport for immunology applications; built by Ampleia as part of its rare-disease venture-builder portfolio.
  • Stealth Biotech (Neurosciences) Stealth-stage company developing a gene-therapy platform enabling large payload delivery for neurosciences applications; built by Ampleia within its rare-disease venture-builder portfolio.
  • Genosafe Contract research organization (CRO) specializing in gene and cell therapy, founded in 2003; part of Ampleia's venture-builder legacy portfolio. Serge Braun serves as its President.
  • Yposkesi Contract development and manufacturing organization (CDMO) for gene and cell therapy, created in 2016; part of Ampleia's venture-builder legacy portfolio.
  • Atamyo Therapeutics Gene therapy company focused on muscular dystrophies, founded in 2020, advancing programs for LGMD-R5 and other rare neuromuscular diseases; built from Genethon research by Ampleia's venture builder.

Quantifiable outcome

  • 218k€ annual price per patient vs 13k€ for common diseases
  • +2 more outcomes

Companies that use Ampleia

Customer profile

Segments3 records

Ideal customer profiles3 records

Ampleia technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Ampleia partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered portfolio and core.

  • Atamyo TherapeuticsportfolioStrategic or Co-development Partner · 1 January 2020Atamyo, created in 2020, focuses on gene therapy for muscular dystrophies. Pierre-Albert Colcomb was instrumental in Atamyo's creation. Portfolio company building on Genethon research.
  • YposkesiportfolioStrategic or Co-development Partner · 1 January 2016Yposkesi, created in 2016, is a CDMO for gene and cell therapy. Part of Ampleia's venture-builder legacy portfolio of companies.
  • GenosafeportfolioStrategic or Co-development Partner · 1 January 2003Genosafe, founded in 2003, is a CRO for gene and cell therapy. Serge Braun is President of Genosafe. Part of Ampleia's venture-builder legacy.
  • AFM-TelethoncoreStrategic or Co-development PartnerAFM-Telethon is a renowned partner fighting rare diseases for 65+ years since 1958. They have invested €1.7b in R&D for rare diseases, have 550+ FTEs and 215k+ volunteers, and maintain a wide international network. Ampleia's legacy and track-record is deeply connected to AFM-Telethon's expertise.
  • GenethoncoreStrategic or Co-development PartnerGenethon, founded in 2003, is a CRO for gene and cell therapy. Ampleia President Alexandre Lemoalle is Head of Strategic Projects at Genethon. Genethon's foundational research has helped advance sarcoglycan-targeting gene therapy approaches through Atamyo Therapeutics.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Ampleia competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Ampleia social profiles

Digital presence

Ampleia compliance and trust

Trust signal

Compliance1 record

Ampleia financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ampleia leadership team

Management profile

Number of profiles

Profiles9 records

Ampleia funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ampleia M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ampleia

What does Ampleia do?

Ampleia is a venture builder that identifies breakthrough research teams in rare diseases worldwide, assembles execution-focused teams of operators, scientists, and investors, and advances programs through clinical development to create biotech companies. The firm manages a portfolio of portfolio companies and spinoffs (Genosafe, Yposkesi, Atamyo Therapeutics) plus active stealth-stage biotechs in immunology and neurosciences, capturing equity and licensing/royalty returns while delivering clinical benefits to patients with rare diseases.

Is Ampleia a public or private company?

Ampleia is a private company. It is classified as unknown and is currently operating.

When was Ampleia founded?

Ampleia was founded in 2023. It employs 1 to 10 people.

Where is Ampleia based?

Ampleia is headquartered in Évry, France, in the Europe region.

How does Ampleia make money?

One revenue line is on record: equity returns from portfolio companies.

Does Ampleia have an API?

No public API is recorded for Ampleia.

What industry is Ampleia in?

Ampleia's product category is Biotech Venture Building. Its primary akta.pro industry code is HLAIALAH, Regulatory Strategy & IND/NDA/BLA Submissions Support, with a secondary code of HLAGANAI, Bioinformatics, Multi-Omics Data Analysis & Interpretation Services. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales